Atovaquone proguanil hydrochloride: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Atovaquone proguanil hydrochloride}} | {{Atovaquone proguanil hydrochloride}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Overview== | ==Overview== | ||
Latest revision as of 18:04, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Category
US Brand Names
MALARONE®
FDA Package Insert
Bold Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
